SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

DOG CRYPTO is generating buzz as C2 Blockchain continues to expand its significant holdings, signaling growing institutional interest in the Bitcoin-native asset. The community is deeply divided, with a passionate "DOG Army" emphasizing its unique Bitcoin foundation and long-term potential, often viewing price dips as buying opportunities. Conversely, skeptics actively caution against its volatility and sustainability, contributing to a vibrant, contested discourse around its future.

Rockwell Automation, Inc. engages in the provision of industrial automation and digital transformation services. It operates through the following segments: Intelligent Devices, Software & Control, and Lifecycle Services. The Intelligent Devices segment includes drives, motion, advanced material handling, safety, sensing, industrial components, and configured-to-order products. The Software & Control segment includes control and visualization software and hardware, digital twin, simulation and information software, and network and security infrastructure. The Lifecycle Services segment includes digital consulting, professional services including engineered-to-order solutions, recurring services including cybersecurity, safety, remote monitoring, and asset management, and the Sensia joint venture. The company was founded by Lynde Bradley and Stanton Allen in 1903 and is headquartered in Milwaukee, WI.

Rockwell Automation Inc

Rockwell Automation is trending due to a wave of positive analyst upgrades and recent strong earnings performance, affirming its leadership in industrial automation and AI robotics. The community is actively discussing the company's pivotal role in the accelerating Industry 4.0 transformation and strategic collaborations, particularly with NVIDIA, as key growth drivers. Investors are recognizing Rockwell's potential as a beneficiary of manufacturing reshoring and the broader automation theme.

Polygon

Polygon ($POL) is currently trending with community members expressing frustration over its recent price performance, leading to questions about its value proposition. A significant talking point revolves around Polygon's co-founder exploring a return to the original $MATIC ticker to address widespread user confusion and capitalize on existing brand familiarity. This highlights a tension between the network's technical advancements and market perception, despite past high-profile partnerships that long-term holders often emphasize.

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Cytokinetics Inc

Cytokinetics is a major trending topic following the FDA approval of MYQORZO (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy, positioning it as a potentially superior option to existing treatments like Camzyos due to its differentiated label and dosing. The community is actively debating its competitive advantages, including a simpler administration profile despite a black box warning, which is driving significant speculation around potential mergers and acquisitions. While many anticipate a strong market entry, discussions also highlight the need for strategic partnerships to support its commercial launch and manage cash burn.

The Internet Computer is a decentralized cloud blockchain designed to run applications, websites, and backend systems fully on-chain. Its architecture provides robust security, resilience, and built-in multi-chain support.  A key focus of the network is enabling a “self-writing cloud,” where AI tools allow users generate applications through natural-language instructions.  Developers and users can experiment with the platform using AI app-generation tools like caffeine.ai or by writing serverless code directly through online IDEs such as icp.ninja.  The ICP token is used to pay for computation (through a burn-based model) and to participate in network governance through staking.

Internet Computer

Internet Computer (ICP) is trending as its community fiercely debates significant technological advancements like Caffeine AI, Chain Fusion, and growing ecosystem projects against persistent concerns over token supply dynamics and price volatility. Supporters emphasize ICP's unique fully on-chain architecture for apps and AI, positioning it as a highly undervalued "world computer" challenging traditional cloud services, while critics focus on perceived price manipulation and token minting.

Teradyne, Inc. engages in the development and sale of automatic test systems. It operates through the following business segments: Semiconductor Test, Robotics, and All Other. The Semiconductor Test segment designs, manufactures, and markets semiconductor test products and services. The Robotics segment includes operations related to the design, manufacturing, and marketing of collaborative robotic arms, autonomous mobile robots, and advanced robotic control software. The company was founded by Alexander V. d'Arbeloff and Nicholas DeWolf in 1960 and is headquartered in North Reading, MA.

Teradyne, Inc.

Teradyne is gaining significant attention following multiple analyst upgrades and robust performance driven by strong AI-related demand in its semiconductor testing and robotics segments. The community is actively discussing the company's pivotal role in the AI supercycle, with conversations highlighting its market position and growth trajectory despite some caution regarding short-term overbought conditions.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Uniswap is trending as the community eagerly awaits the outcome of a key governance vote on the "UNIfication proposal," which aims to activate the protocol fee switch and introduce a substantial token burn. This pivotal update is fueling strong bullish sentiment, with many anticipating enhanced token value and deflationary mechanics that could significantly reprice this DeFi cornerstone. Many believe this move will align incentives and solidify UNI's long-term position within the decentralized finance ecosystem.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata (INOD) is generating significant buzz as investors eagerly await a promised "strategic partnership" with a market-leading military contractor for AI solutions, expected before year-end. This potential "game-changer" is driving intense community debate, with bulls anticipating substantial revenue growth in the booming, secure government AI data training sector. However, skeptics express frustration over past delays and the stock's recent struggles amidst broader small-cap market volatility.

BitcoinII (BC2) is a proof-of-work, peer-to-peer digital currency that mirrors Bitcoin’s original monetary and consensus rules—21M max supply, ~10-minute blocks, halving every four years, and difficulty retargets every 2016 blocks—launched on a clean genesis with no premine and no ICO. The goal is simple: provide a familiar, dependable payments network focused on money, not data storage. BC2 supports SegWit and Taproot and is intentionally compatible with common Bitcoin tooling so miners, users, and exchanges can run it with minimal friction. It is positioned as a “sister chain,” not a replacement or competitor: another network using the same proven design so people can transact easily, run nodes on modest hardware, and participate from day one.

BitcoinII

BitcoinII ($BC2) is gaining traction as a "second chance" for investors who missed early Bitcoin, with the community actively promoting it as an un-bloated, pure version of the original. Supporters emphasize its identical nature to Bitcoin, highlighting a new genesis block and zero pre-mine, alongside its growing number of mining pools and ongoing exchange listings.

Rain Enhancement Technologies Holdco, Inc. develops, manufactures, and commercializes ionization rainfall generation technology to provide additional rainfall for industries, supranational organizations, countries, and localities. The company is headquartered in Naples, FL.

Rain Enhancement Technologies Holdco Inc. - Ordinary Shares - Class A

Rain Enhancement Technologies is currently trending due to positive indications from its initial U.S. weather modification installations and a strategic board appointment, signaling commercial acceleration. Community chatter is intensely focused on the stock's exceptionally tight float and high cost to borrow, fueling strong speculation for a significant short squeeze. A key discussion also involves differentiating this innovative weather enhancement company from a similarly-named, delisted biotech often confused with the ticker.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Assenagon Asset Management S.A. Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Assenagon Asset Management S.A. reduced its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 14.6% during the 3rd quarter, according to its most recent filing with the...

Q4 Earnings Estimate for BCRX Issued By HC Wainwright

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Analysts at HC Wainwright issued their Q4 2025 earnings per share estimates for shares of BioCryst Pharmaceuticals in a report issued on...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Moderate Buy" from Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fourteen ratings firms that are currently covering the...

<ul class="summary-bullets"><li>BioCryst said the approval follows positive interim data from a trial that showed the drug is safe and well-tolerated.</li><li>The company is also seeking approval for the drug’s use in the targeted age group in Europe, Japan, Canada, and other countries.&nbsp;</li><li>Orladeyo in capsule form is already FDA-approved for treating the disorder in those over 12 years of age.&nbsp;</li></ul>BioCryst Pharmaceuticals, Inc. (BCRX) has received approval from the U.S. Food and Drug Administration (FDA) for Orladeyo, an oral pellet formulation for the treatment of a rare genetic disorder in children.The approval comes after positive interim data from the APeX-P trial, which showed it is safe and well-tolerated and effectively reduces monthly HAE attacks in young children, the company said in a statement.BioCryst has also filed an application for the drug’s use with the European Medicines Agency and the Japan Pharmaceutical and Medical Devices Agency. The company said it is exploring additional regulatory filings in other global territories, including Canada.Shares of <a href="https://stocktwits.com/symbol/BCRX">BCRX</a> jumped over 4% on Friday morning at the time of writing.<h2 class="st-heading-2">Breakthrough Treatment For Young Children</h2>Hereditary angioedema (HAE) is a rare genetic disorder that can cause sudden and severe swelling in the skin, face, limbs, gut, and air pathways with potential life-threatening consequences.Orladeyo will become the first approved oral drug for the treatment of hereditary angioedema (HAE) in children aged 2 to 12, the company said. All other treatments for HAE in the market for the targeted demographic are currently administered intravenously or through injections.A capsule formulation of Orladeyo for treating HAE in children over 12 years and older adults received FDA approval in December 2020.“As we mark five years since ORLADEYO first transformed care for those with HAE ages 12 and older, this approval extends the benefits of oral prophylactic therapy to a vulnerable and important part of the HAE community, children ages 2 to less than 12. We couldn’t be more excited to bring this treatment option to these kids and their caregivers,” said Jon Stonehouse, chief executive officer of BioCryst.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, BCRX was among the top five trending stocks on Friday morning. The retail sentiment around BCRX jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained ‘high’ at the time of writing.<figure class="image"><img style="aspect-ratio:1267/136;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_12_at_6_36_49_PM_png_130ee4212d.webp" alt="BCRX sentiment and message volume on Stocktwits. " width="1267" height="136"></figure>One Stocktwits user commended the FDA news.<stembedurl>https://stocktwits.com/Kiwiarse/message/638975638</stembedurl>Shares of BCRX are down over 3% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

CANADA - 2025/10/14: In this photo illustration, the BioCryst Pharmaceuticals (Bio Cryst) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today?

The FDA has approved the use of Orladeyo, an oral drug, for children aged 2–12 with a rare genetic disorder.

Equity

Hood River Capital Management LLC Buys New Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Hood River Capital Management LLC purchased a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the 2nd quarter, according to its most recent 13F filing with the...

BioCryst Pharmaceuticals, Inc. $BCRX Shares Acquired by Russell Investments Group Ltd.

Russell Investments Group Ltd. increased its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 326.1% during the 2nd quarter, according to its most recent filing with...

JPMorgan Chase & Co. Grows Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

JPMorgan Chase & Co. boosted its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 48.7% during the 2nd quarter, according to its most recent 13F filing with the...

BioCryst Pharmaceuticals, Inc. $BCRX Position Increased by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership grew its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 2,103.7% in the 2nd quarter, according to the company in its most recent...

BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Alane Barnes Sells 19,770 Shares

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 19,770 shares of the business's stock in a transaction on Wednesday, December 3rd. The stock was sold at an...

Insider Selling: BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells 50,906 Shares of Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 50,906 shares of the company's stock in a transaction dated Tuesday, December 2nd. The stock was sold at an...

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

BCRX
Biocryst Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BCRX News

BCRXBiocryst Pharmaceuticals Inc.